Wall Street analysts expect Merrimack Pharmaceuticals Inc (NASDAQ:MACK) to post sales of $33.00 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Merrimack Pharmaceuticals’ earnings. Merrimack Pharmaceuticals posted sales of $61.24 million during the same quarter last year, which would suggest a negative year over year growth rate of 46.1%. The firm is expected to announce its next earnings report on Wednesday, March 7th.
On average, analysts expect that Merrimack Pharmaceuticals will report full-year sales of $33.00 million for the current fiscal year. For the next financial year, analysts expect that the company will post sales of $0.00 per share. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Merrimack Pharmaceuticals.
Merrimack Pharmaceuticals (NASDAQ:MACK) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.88) by $1.48.
Merrimack Pharmaceuticals (NASDAQ MACK) opened at $10.82 on Friday. Merrimack Pharmaceuticals has a 1-year low of $10.04 and a 1-year high of $39.90. The stock has a market cap of $145.46, a price-to-earnings ratio of -1.48 and a beta of 1.72. The company has a current ratio of 3.35, a quick ratio of 3.35 and a debt-to-equity ratio of 0.45.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Rubric Capital Management LP acquired a new position in shares of Merrimack Pharmaceuticals during the third quarter valued at $4,913,000. Newtyn Management LLC acquired a new position in shares of Merrimack Pharmaceuticals during the third quarter valued at $5,671,000. Dimensional Fund Advisors LP acquired a new position in shares of Merrimack Pharmaceuticals during the third quarter valued at $376,000. Macquarie Group Ltd. acquired a new stake in Merrimack Pharmaceuticals in the third quarter worth about $137,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in Merrimack Pharmaceuticals by 14.8% in the second quarter. The Manufacturers Life Insurance Company now owns 113,235 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 14,591 shares during the period. 50.14% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This report was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.tickerreport.com/banking-finance/3146755/33-00-million-in-sales-expected-for-merrimack-pharmaceuticals-inc-mack-this-quarter.html.
Merrimack Pharmaceuticals Company Profile
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.